Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Depression
- Chronic Disease
- Internal Medicine
- Asthma
- Gastroenterology
- Pharmacology and Therapeutics
- Neurology
- Transplantation Medicine
Abstract
Citation: Ann Clin Case Rep. 2019;4(1):1749.DOI: 10.25107/2474-1655.1749
Renal Failure in a Patient with Ibrutinib Refractory Chronic Lymphocytic Leukemia
Paola Casciani, Massimiliano Postorino, Francesca Rossi, Sergio Tripodi, Annalisa Biagi, Lisa Mercante, Roberta Laureana, Enrico Santinelli, Maria Ilaria Del Principe, Valter Gattei and Giovanni Del Poeta
Department of Biomedicine and Prevention, Università Tor Vergata, Italy IRCCS Centro di Riferimento Oncologico, Italy UOC Pathological Anatomy, Azienda Ospedaliera Universitaria, Italy
*Correspondance to: Giovanni Del Poeta
PDF Full Text Case Report | Open Access
Abstract:
The incidence of a renal lymphocytic infiltration in Chronic Lymphocytic Leukemia (CLL) is a fairly common phenomenon, found in a variable percentage of cases, as a result of autopsy studies. However, it is uncommon the association of the infiltrate with specific renal histopathological alterations, such as a Granulomatous Interstitial Nephritis (GIN), with severe kidney function impairment. We describe a patient with progressive TP53 mutated CLL who developed acute renal failure due to leukemic infiltration associated with GIN during treatment with ibrutinib, the new inhibitor of the Bruton’s tyrosine kinase. After stopping ibrutinib, the patient obtained a complete remission with high doses of prednisone plus chemoimmunotherapy, but recently he underwent relapse treated now with venetoclax plus prednisone.
Keywords:
Cite the Article:
Casciani P, Postorino M, Rossi F, Tripodi S, Biagi A, Mercante L, et al. Renal Failure in a Patient with Ibrutinib Refractory Chronic Lymphocytic Leukemia. Ann Clin Case Rep. 2019; 4: 1749.